Sugi Predict

Sugi Predict / Compounds / SCHEMBL545951

SCHEMBL545951

SCHEMBL545951

CN(C)c1n[c]nc2[nH]cnc12

nearest known ligand 0.37

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ PDPK1 O15530 2/20 0.37
▸ CHEK1 O14757 1/20 0.37
▸ AURKA O14965 1/20 0.37
▸ CHEK2 O96017 1/20 0.37
▸ HSP90AA1 P07900 1/20 0.37
▸ HSP90AB1 P08238 1/20 0.37
▸ PRKACA P17612 1/20 0.37
▸ CCNE1 P24864 1/20 0.37
▸ CDK2 P24941 1/20 0.37
▸ MARK3 P27448 1/20 0.37
▸ RPS6KA3 P51812 1/20 0.37
▸ PRKCD Q05655 1/20 0.37
▸ LRRK2 Q5S007 1/20 0.37
▸ MARK2 Q7KZI7 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2139275 0.75 PDPK1 (0.35) PDPK1
Dimethyladenine SCHEMBL152593 0.73 LRRK2 (0.52) PDPK1CHEK1AURKACHEK2HSP90AA1
Dimethyladenine SCHEMBL11157543 0.72 LRRK2 (0.50) PDPK1CHEK1AURKACHEK2HSP90AA1
SCHEMBL546074 0.72 XDH (0.35) PDPK1
SCHEMBL442759 0.71 PNP (0.32) PDPK1LRRK2
SCHEMBL8169178 0.71 BCL2 (0.34) —
SCHEMBL9426162 0.71 — —
SCHEMBL3444335 0.71 CSNK2A1 (0.34) AURKAPRKACARPS6KA3LRRK2
SCHEMBL545952 0.70 PDPK1 (0.58) PDPK1CHEK1AURKACHEK2HSP90AA1
SCHEMBL20793714 0.69 PDPK1 (0.36) PDPK1CHEK1AURKACHEK2HSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070179100-A1 Protected monomers ALNYLAM PHARMACEUTICALS, INC. 2007-08-02 — — US claimed
WO-2007014054-A2 BENZENESULFONAMIDE INHIBITOR OF CCR2 CHEMOKINE RECEPTOR GLAXO GROUP LIMTED (GB) 2007-02-01 — — WO claimed
EP-1625138-A2 PROTECTED MONOMERS Alnylam Pharmaceuticals Inc. (US) 2006-02-15 — — EP claimed
WO-2004094345-A2 PROTECTED MONOMERS ALNYLAM PHARMACEUTICALS INC. (US) 2004-11-04 — — WO claimed
US-20220403377-A1 MODIFIED iRNA AGENTS ALNYLAM PHARMACEUTICALS, INC. 2022-12-22 — — US disclosed
US-11312957-B2 Modified iRNA agents ALNYLAM PHARMACEUTICALS, INC. (US) 2022-04-26 — — US disclosed
US-20210254065-A1 iRNA AGENTS WITH BIOCLEAVABLE TETHERS ALNYLAM PHARMACEUTICALS, INC. 2021-08-19 — — US disclosed
US-20210177757-A1 EXOSOMES FOR DELIVERY OF THERAPEUTIC AGENTS PURETECH LYT, INC. (US) 2021-06-17 — — US disclosed
US-11015194-B2 iRNA agents with biocleavable tethers ALNYLAM PHARMACEUTICALS, INC. (US) 2021-05-25 — — US disclosed
US-10676740-B2 Modified iRNA agents ALNYLAM PHARMACEUTICALS, INC. (US) 2020-06-09 — — US disclosed
US-10550386-B2 Monomers and oligonucleotides comprising cycloaddition adduct(s) ALNYLAM PHARMACEUTICALS, INC. (US) 2020-02-04 — — US disclosed
US-20190345498-A1 MODIFIED iRNA AGENTS BANK OF AMERICA, N.A. 2019-11-14 — — US disclosed
WO-2005004794-A2 METHOD OF TREATING NEURODEGENERATIVE DISEASE ALNYLAM PHARMACEUTICALS INC. (US) 2005-01-20 — — WO disclosed
WO-2004094595-A2 MODIFIED iRNA AGENTS ALNYLAM PHARMACEUTICALS INC. (US) 2004-11-04 — — WO disclosed
WO-2004094345-A2 PROTECTED MONOMERS ALNYLAM PHARMACEUTICALS INC. (US) 2004-11-04 — — WO disclosed
WO-2004091515-A2 iRNA CONJUGATES ALNYLAM PHARMACEUTICALS, INC. (US) 2004-10-28 — — WO disclosed
WO-2004090108-A2 IRNA CONJUGATES ALNYLAM PHARMACEUTICALS (US) 2004-10-21 — — WO disclosed
WO-2004080406-A2 THERAPEUTIC COMPOSITIONS ALNYLAM PHARMACEUTICALS (US) 2004-09-23 — — WO disclosed
EP-0766683-A1 NOVEL SUBSTITUTED PURINYL DERIVATIVES WITH IMMUNOMODULATING ACTIVITY BIOCHEM PHARMA INC (CA) 1997-04-09 — — EP disclosed
WO-1995035297-A1 NOVEL SUBSTITUTED PURINYL DERIVATIVES WITH IMMUNOMODULATING ACTIVITY BIOCHEM PHARMA INC. (CA) 1995-12-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220403377-A1 MODIFIED iRNA AGENTS NCL, HNRNPA0, HNRNPA1 PDPK1 2827/4885CHEK1 1535/4885AURKA 992/4885
US-20210177757-A1 EXOSOMES FOR DELIVERY OF THERAPEUTIC AGENTS EXOSC5, EXOSC9, EXOSC10 PDPK1 3389/4885CHEK1 4530/4885AURKA 1439/4885
US-20190345498-A1 MODIFIED iRNA AGENTS NCL, HNRNPA0, HNRNPA1 PDPK1 2827/4885CHEK1 1535/4885AURKA 992/4885
US-10550386-B2 Monomers and oligonucleotides comprising cycloaddition adduct(s) FANCI, PCNA, DNMT1 PDPK1 4568/4885CHEK1 1989/4885AURKA 958/4885
US-10676740-B2 Modified iRNA agents NCL, HNRNPA0, HNRNPA1 PDPK1 2827/4885CHEK1 1535/4885AURKA 992/4885
US-11312957-B2 Modified iRNA agents NCL, HNRNPA0, HNRNPA1 PDPK1 2827/4885CHEK1 1535/4885AURKA 992/4885
US-20070179100-A1 Protected monomers PCNA, POLN, PARP1 PDPK1 4540/4885CHEK1 1607/4885AURKA 3471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.